Quantifying Clinical Relevance in the Treatment of Schizophrenia

被引:90
作者
Correll, Christoph U. [1 ,2 ,3 ,4 ]
Kishimoto, Taishiro
Nielsen, Jimmi [5 ]
Kane, John M. [2 ,3 ,4 ]
机构
[1] N Shore Long Isl Jewish Hlth Syst, Zucker Hillside Hosp, Div Psychiat, Psychiat Res, Glen Oaks, NY 11004 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Feinstein Inst Med Res, Manhasset, NY USA
[4] Hofttra N Shore LIJ Sch Med, Hempstead, NY USA
[5] Aarhus Univ Hosp, Aalborg Psychiat Hosp, Unit Psychiat Res, Aalborg, Denmark
关键词
adverse effects; antipsychotics; efficacy; effectiveness; measurement; quantification; real world; schizophrenia; QUALITY-OF-LIFE; DEFINING TREATMENT REFRACTORINESS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; RATING-SCALE; 1ST-EPISODE PSYCHOSIS; MAINTENANCE TREATMENT; NEUROPSYCHOLOGICAL STATUS; COGNITIVE IMPAIRMENT; ANTIPSYCHOTIC AGENTS;
D O I
10.1016/j.clinthera.2011.11.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: To optimize the management of patients with schizophrenia, quantification of treatment effects is crucial. While in research studies, the use of quantitative assessments is ubiquitous, this is not the case in routine clinical practice, creating an important translational practice gap. Objective: The aim of this study was to examine the relevance, methodology, reporting, and application of measurement-based approaches in the management of schizophrenia. Methods: We summarized methodological aspects in the assessment of therapeutic and adverse antipsychotic effects in schizophrenia, including definitions and methods of measurement-based assessments and factors that can interfere with the valid quantification of treatment effects. Finally, we proposed pragmatic and clinically meaningful ways to measure and report treatment outcomes. Results: Although rating scales are ubiquitous in schizophrenia research and provide the evidence base for treatment guidelines, time constraints and lack of familiarity with and/or training in validated assessment tools limit their routine clinical use. Simple but valid assessment instruments need to be developed and implemented to bridge this research-practice gap. In addition, results from research trials need to be communicated in clinically meaningful ways, including the reporting of effect sizes, numbers-needed-to-treat and -harm, confidence intervals, and absolute risk differences. Some important outcomes, such as treatment response, should be reported in escalating intervals using incrementally more stringent psychopathology improvements. Even with quantification, it remains challenging to weigh individual efficacy and adverse effect outcomes against one another and decide on the targeted or desired improvement or outcomes while also incorporating these in patient-centered and shared decision methods. Conclusions: Quantification of treatment effects in schizophrenia is relevant for patient management, research, and the evaluation of health care systems. Beyond consensus about meaningful outcomes definitions, reporting strategies, pragmatic tool development and implementation, the discovery of novel treatment mechanisms and related biomarkers is hoped to advance measurement-based approaches in schizophrenia and thereby improve patient outcomes. (Clin Ther. 2011;33:B16-B39) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:B16 / B39
页数:24
相关论文
共 132 条
[1]   A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
SCHISSEL, B .
SCHIZOPHRENIA RESEARCH, 1990, 3 (04) :247-251
[2]   Remission in schizophrenia: Proposed criteria and rationale for consensus [J].
Andreasen, NC ;
Carpenter, WT ;
Kane, JM ;
Lasser, RA ;
Marder, SR ;
Weinberger, DR .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (03) :441-449
[3]  
Andreasen NC., 1984, SCALE ASSESSMENT POS
[4]  
[Anonymous], PSYCHIAT RES
[5]  
[Anonymous], 1989, BRIT J PSYCHIAT
[6]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[7]  
[Anonymous], PAT REP OUTC MEAS US
[8]  
Antonovsky A., 1987, Unraveling the Mystery of Health: how People Manage Stress and Stay Well
[9]   A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study [J].
Arato, M ;
O'Connor, R ;
Meltzer, HY .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (05) :207-215
[10]   Development and validation of a measure of patients' knowledge about schizophrenia [J].
Ascher-Svanum, H .
PSYCHIATRIC SERVICES, 1999, 50 (04) :561-563